WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007004979) METHOD FOR MODULATING RESPONSIVENESS TO STEROIDS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/004979    International Application No.:    PCT/SE2006/050232
Publication Date: 11.01.2007 International Filing Date: 30.06.2006
IPC:
A61K 38/00 (2006.01), A61P 29/00 (2006.01)
Applicants: INDEX PHARMACEUTICALS AB [SE/SE]; Scheeles Väg 1, S-171 77 Stockholm (SE) (For All Designated States Except US).
SPIIK, Ann-Kristin [SE/SE]; (SE) (For US Only).
LÖFBERG, Robert [SE/SE]; (SE) (For US Only).
BANDHOLTZ, Lisa, Charlotta [SE/SE]; (SE) (For US Only).
VON STEIN, Oliver [SE/SE]; (SE) (For US Only)
Inventors: SPIIK, Ann-Kristin; (SE).
LÖFBERG, Robert; (SE).
BANDHOLTZ, Lisa, Charlotta; (SE).
VON STEIN, Oliver; (SE)
Agent: BERGENSTRÅHLE & LINDVALL AB; Box 17704, S-118 93 Stockholm (SE)
Priority Data:
60/696,050 01.07.2005 US
Title (EN) METHOD FOR MODULATING RESPONSIVENESS TO STEROIDS
(FR) METHODE DE MODULATION DE LA REPONSE AUX STEROIDES
Abstract: front page image
(EN)The present invention makes it possible to enhance steroid efficacy in a steroid refractory patient afflicted with an inflammatory condition not responding or responding poorly or inadequately to anti-inflammatory treatment, by administering an effective amount of an oligonucleotide having the sequence 5'-Xm-TTCGT-Yn-3' to 5 said patient, wherein X is A, T, C or G, Y is A, T, C or G, m=0-7, n=0-7 and wherein at least one CG dinucleotide is unmethylated. The invention also encompasses the use of said oligonucleotide for the manufacture of pharmaceuticals.
(FR)La présente invention concerne l'amélioration de l'efficacité des stéroïdes chez un patient réfractaire aux stéroïdes souffrant d'un état inflammatoire ne répondant pas ou peu ou de manière inadéquate à un traitement anti-inflammatoire, par administration d'une quantité efficace d'un oligonucléotide présentant la séquence 5'-Xm-TTCGT-Yn-3' à 5 audit patient, dans laquelle X est A, T, C ou G, Y est A, T, C ou G, m=0-7, n=0-7, et au moins un dinucléotide CG est non méthylé. L'invention concerne également l'utilisation dudit oligonucléotide dans la fabrication de produits pharmaceutiques.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)